DNA sequencing can be used to identify the underlying genetic cause of many rare types of chronic kidney disease, leading to better treatment, finds a new study from Columbia University.

In a phase three clinical trial, sorafenib stopped progression of desmoid tumors for two years in 80 percent of patients who completed treatment.

Look back at the research and education news from CUIMC that captured the attention of Newsroom readers and the nation's journalists in 2018.